Jupiter Neurosciences (JUNS) EBT (2023 - 2026)

Jupiter Neurosciences (JUNS) has reported EBT for 4 consecutive years, with -$2.8 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBT fell 25.32% year-over-year to -$2.8 million in Q2 2026; TTM through Jun 2026 was -$10.2 million, a 74.49% decrease from a year earlier, with the FY2025 full-year figure at -$9.0 million, down 169.18% from the prior year.
• EBT was -$2.8 million for Q2 2026 at Jupiter Neurosciences, up from -$2.9 million in the prior quarter.
• Over five years, EBT peaked at -$600906.0 in Q3 2024 and troughed at -$2.9 million in Q4 2025.
• A 4-year average of -$1.6 million and a median of -$1.5 million in 2023 frame the typical range for EBT.
• Across the five-year window, EBT jumped 60.53% in 2024 and tumbled 280.76% in 2025, its largest moves.
• Over 4 years, EBT stood at -$638354.0 in 2023, then slumped by 132.39% to -$1.5 million in 2024, then tumbled by 93.55% to -$2.9 million in 2025, then grew by 1.66% to -$2.8 million in 2026.
• The last three EBT figures came in at -$2.8 million (Q2 2026), -$2.9 million (Q4 2025), and -$2.3 million (Q3 2025), per Business Quant data.